- Stocks
- Pharma & Healthcare
- Krsnaa Diagnostics
Krsnaa Diagnostics share price
NSE: KRSNAAPharma & HealthcareDiagnostics & Research
Krsnaa Diagnostics at a glance
Krsnaa Diagnostics (NSE: KRSNAA) closed at ₹510.75 on 22 Oct 2026, down 0.79% on the day. With a market capitalisation of ₹1,657 Cr, it ranks 1218th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 16.5× trailing earnings, against a return on equity of 10.3% in FY26. Over the past year the share price has fallen 38.5%. Its 52-week range is ₹504.00 (21 Oct 2026) to ₹838.00 (17 Nov 2025); the last close is 39.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹193 Cr (+3.5% year on year) and net profit ₹42 Cr (+101.7%), on a consolidated basis. Promoters held 27.11% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,657 CrRank 1218 on NSE
- P/E (trailing)
- 16.5×
- Price to book
- 1.72×FY26
- EPS (TTM)
- ₹31.31to Q4 FY26
- ROE
- 10.3%FY26
- ROCE
- 10.6%FY26
- Debt to equity
- 0.55FY26
- Net profit margin
- 13.1%FY26
- Book value / share
- ₹302.23FY26
- 52-week high
- ₹838.0017 Nov 2025
- 52-week low
- ₹504.0021 Oct 2026
- 1-year return
- −38.5%
- RSI (14-day)
- 35.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.79% | −2.9% | −7.5% | −6.2% | −38.5% |
Krsnaa Diagnostics quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹170 Cr | ₹186 Cr | ₹175 Cr | ₹186 Cr | ₹193 Cr | ₹206 Cr | ₹181 Cr | ₹193 Cr |
| Revenue YoY | +22.0% | +19.9% | +10.2% | +11.9% | +13.4% | +10.5% | +3.8% | +3.5% |
| Net profit | ₹18 Cr | ₹20 Cr | ₹19 Cr | ₹21 Cr | ₹21 Cr | ₹24 Cr | ₹15 Cr | ₹42 Cr |
| Net profit YoY | +22.4% | +86.7% | +49.7% | +10.4% | +14.5% | +22.1% | −21.1% | +101.7% |
| Net margin | 10.5% | 10.5% | 11.1% | 11.1% | 10.6% | 11.6% | 8.5% | 21.7% |
| EPS | ₹5.55 | ₹6.07 | ₹6.01 | ₹6.40 | ₹6.35 | ₹7.38 | ₹4.72 | ₹12.86 |
Krsnaa Diagnostics financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹455 Cr | ₹487 Cr | ₹620 Cr | ₹717 Cr | — |
| Operating profit | ₹87 Cr | ₹80 Cr | ₹70 Cr | ₹103 Cr | — |
| Net profit | ₹68 Cr | ₹62 Cr | ₹57 Cr | ₹78 Cr | — |
| EPS (₹) | ₹23.00 | ₹20.00 | ₹18.00 | ₹24.00 | — |
| Cash from operations | ₹128 Cr | ₹76 Cr | ₹24 Cr | ₹87 Cr | — |
| Total debt | ₹20 Cr | ₹11 Cr | ₹6 Cr | ₹19 Cr | ₹468 Cr |
| Shareholders' equity | ₹684 Cr | ₹739 Cr | ₹810 Cr | ₹883 Cr | ₹980 Cr |
Krsnaa Diagnostics shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 27.24% | 27.11% | 27.11% | 27.11% | 27.11% | 27.11% |
| Foreign institutions | 3.55% | 3.40% | 3.67% | 4.17% | 3.91% | 4.28% |
| Domestic institutions | 14.26% | 14.24% | 14.96% | 13.86% | 13.89% | 14.51% |
| Non-institutions | 54.94% | 55.25% | 54.26% | 54.85% | 55.08% | 54.09% |
Krsnaa Diagnostics vs peers
The listed Pharma & Healthcare companies nearest to Krsnaa Diagnostics by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| WINDLASWindlas Biotech | ₹885.70 | −0.20% | −2.2% | ₹1,828 Cr | 28.4 | — |
| TITANBIOTitan Biotech | — | — | — | ₹1,793 Cr | — | — |
| FISCHERFischer Medical Ventures | ₹26.21 | +3.80% | −72.0% | ₹1,715 Cr | 58.2 | — |
| NGLFINENGL Fine-Chem | ₹2,717.20 | +3.00% | +80.2% | ₹1,679 Cr | 34.8 | — |
| KRSNAAKrsnaa Diagnostics | ₹510.75 | −0.79% | −38.5% | ₹1,657 Cr | 16.5 | — |
| JLHLJupiter Life Line Hospitals | ₹244.75 | −0.87% | −20.0% | ₹1,605 Cr | 8.3 | — |
| ASTECAstec LifeSciences | ₹700.20 | +6.41% | −5.5% | ₹1,560 Cr | — | — |
Ask anything about Krsnaa Diagnostics
Pivot answers on the live chart with evidence you can check, and tests strategies against KRSNAA's own history. Try: “Why has KRSNAA moved over the last three months?” · “Backtest a 50-day moving-average crossover on KRSNAA over five years” · “Compare KRSNAA with WINDLAS on margins and valuation”
Frequently asked questions about Krsnaa Diagnostics
What is the share price of Krsnaa Diagnostics today?
Krsnaa Diagnostics (NSE: KRSNAA) last closed at ₹510.75 on 22 Oct 2026. Its 52-week high is ₹838.00 and its 52-week low is ₹504.00.
What is the market cap of Krsnaa Diagnostics?
Krsnaa Diagnostics' market capitalisation is ₹1,657 Cr (₹1,657 Cr) at the 22 Oct 2026 close, ranking 1218th among the NSE companies Pivot tracks.
What is the P/E ratio of Krsnaa Diagnostics?
Krsnaa Diagnostics trades at a trailing P/E of 16.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 34.8.
What is the ROE and ROCE of Krsnaa Diagnostics?
Return on equity was 10.3% in FY26 and return on capital employed was 10.6% in FY26 (consolidated figures).
Is Krsnaa Diagnostics a debt-free company?
No. Krsnaa Diagnostics' debt-to-equity ratio was 0.55 in FY26, with total debt of ₹468 Cr.
What were Krsnaa Diagnostics' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Krsnaa Diagnostics reported revenue of ₹193 Cr, +3.5% year on year, and net profit of ₹42 Cr, +101.7% year on year.
How has Krsnaa Diagnostics stock performed over the last year?
Krsnaa Diagnostics' share price has fallen 38.5% over the past year, −6.2% over three months and −7.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Krsnaa Diagnostics?
As of 30 Jun 2026: promoters 27.11%, foreign institutions 4.28%, domestic institutions 14.51%, non-institutions 54.09%.
Who are Krsnaa Diagnostics' competitors?
The listed Pharma & Healthcare companies closest to Krsnaa Diagnostics by market cap are Windlas Biotech, Titan Biotech, Fischer Medical Ventures, NGL Fine-Chem, Jupiter Life Line Hospitals and Astec LifeSciences.
Is Krsnaa Diagnostics a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Krsnaa Diagnostics' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KRSNAA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text